Human chronic hepatitis C virus (HCV) infections pose a significant public health threat, necessitating the development of novel treatments and vaccines. HCV infections range from spontaneous resolution to end-stage liver disease. Approximately 10-30 % of HCV infections undergo spontaneous resolution independent of treatment by yet-to-be-defined mechanisms. These individuals test positive for anti-HCV antibodies in the absence of detectable viral serum RNA. To identify genes associated with HCV clearance, this study compared gene expression profiles between current drug users chronically infected with HCV and drug users who cleared their HCV infection. This analysis identified 91 differentially regulated (up-or downregulated by twofold or more) genes potentially associated with HCV clearance. The majority of genes identified were associated with immune function, with the remaining genes categorized either as cancer related or 'other'. Identification of factors and pathways that may influence virus clearance will be essential to the development of novel treatment strategies.
INTRODUCTION
Hepatitis C virus (HCV) is a major cause of liver disease in the USA, with approximately 4 million people chronically infected (Alter, 1997) . Diseases resulting from HCV infections can range from a subclinical anicteric disease to fulminant hepatitis, although the latter is more rare (Hoofnagle, 1997) . Cirrhosis of the liver presents in 20-30 % of persons with chronic HCV, leading to hepatocellular carcinoma or end-stage liver disease that can be treated only by liver transplantation (Hoofnagle, 1997) . In the USA, 85-90 % of HCV infections are associated with injection drug use and related behaviours, including having sex with an injection drug user, sharing contaminated needles and other high-risk behaviours such as multiple sex partners or sex with partners with a history of sexually transmitted diseases (Alter, 1997) .
Spontaneous HCV clearance, defined as individuals having antibodies specific to HCV antigens but no detectable viral RNA, occurs in~10-30 % of HCV-infected, untreated individuals (Shah et al., 2012; Thomas et al., 2000; Villano et al., 1999) . Persons who clear their HCV infections are more likely to be white, have jaundice, have lower peak viral titres and not be infected with human immunodeficiency virus (HIV) (Shah et al., 2012; Thomas et al., 2000; Villano et al., 1999) . The HCV viral genotype has not been shown to have an impact on clearance (Alric et al., 2000; Villano et al., 1999) , but investigations into immunological components associated with clearance have been shown to differ between patients who spontaneously clear HCV and patients who do not (Alric et al., 2000; Balagopal et al., 2010; Mosbruger et al., 2010) .
Various genes have been implicated in mediating host susceptibility/resistance to HCV infections and in affecting disease presentation. However, identification of these genes has been primarily in the context of various states of HCV infection and not based on factors associated with clearance (Balagopal et al., 2010; Honda et al., 2001; Iizuka et al., 2003; Mosbruger et al., 2010; Shackel et al., 2002) . Data from these studies indicated that impaired innate/acquired immunity associated with cytokine responses influence an individual's ability to clear HCV infections.
As no vaccine options exist for the prevention of HCV infections, and patient responses to treatment are highly variable, extremely expensive and have embedded adverse effects (Yu & Chiang, 2010) , additional studies designed to identify novel genetic targets associated with HCV clearance in humans are needed, as the identification of genes differentially expressed or associated with protection/clearance of HCV infections have primarily been carried out in vitro and not in human populations naïve to HCV therapies. This study identified differentially expressed genes between participants presenting with anti-HCV antibodies negative for HCV RNA (defined as HCV viral clearance) and individuals positive for HCV RNA (defined as HCV viral persistence). Identification of these potential target genes or gene products will lead to the discovery of new pathways that can be targeted for the development of potential novel treatment regimens and to a better understanding of the natural progression of HCV infections.
RESULTS

Study population
Participants in this study were 63 % male and 81 % African-American, with a mean age of 45 years. Of the 16 participants, six (38 %) had a history of injection drug use, three (19 %) were men who had sex with men and eight (50 %) had a history of trading sex for money or drugs (Table 1) .
HCV viral load detection
The eight HCV antibody-positive/RNA-positive patients all had detectable viral loads at the time that the array was carried out. Specifically, the range of HCV RNA was 382-17 960 000 IU ml
21
. The eight HCV antibody-positive/ RNA-negative patients were all negative for detectable HCV RNA at a cut-off of 43 IU ml
.
Differential gene expression
A total of 471 genes (Table S1 , available in JGV Online) were differentially expressed between HCV RNA-positive and RNA-negative participants that were significantly upor downregulated at a nominal value of P,0.05. Of the 471 genes, 91 candidate genes had significantly different expression profiles (up-or downregulated by twofold or more) between the two groups (P,0.05, Table 2 ). Onethird of the genes were downregulated and two-thirds were upregulated.
We performed comprehensive bioinformatics analyses to characterize the 91 differentially expressed genes identified. These analyses consisted of three complementary components: (i) identification of overrepresented biological functions/pathways; (ii) identification of transcription factors affecting gene expression profiles; and (iii) gene network analysis to identify interactions between the 91 genes identified (e.g. physical protein-protein interactions), as well as identification of additional genes with the potential of interacting with some of the gene products expressed by the 91 genes identified that may also be predictive of HCV clearance. We first used the Database for Annotation, Visualization and Integrated Discovery (DAVID) method (Huang et al., 2008) to identify biological functional categories, for example, gene ontology (GO) (Ashburner et al., 2000) terms that are enriched with differentially expressed genes. After adjustment for multiple testing, two GO terms, GO:0006955 (immune response) and ). Secondly, the TELiS method (Cole et al., 2005) was used to identify transcription factor binding motifs (TFBMs) overrepresented in the promoter regions of the differentially expressed genes identified (600 bp upstream of each gene's transcription start site). TFBMs for nuclear factor kB (P50.00005), interferonstimulated response element (P50.01) and Ras-responsive element binding protein 1 (P50.04) were found to be overrepresented in the promoters of those genes whose changes in expression were probably driven by these transcription factors. Finally, we performed gene network analysis using the GeneMANIA method (Mostafavi et al., 2008) . GeneMANIA identifies known gene-gene interactions, for example, physical protein-protein interactions or coexpression profiles between the query gene set (i.e. the 91 differentially expressed genes) and predicts additional genes that may be involved in HCV clearance if they are shown to interact with a large number of genes in the query set (Fig. 1) . The most noticeable feature was the subnetwork formed by the IFI gene family (IFI6, IFIT1, IFIT2, IFI35 and others) that were included in the query set and the identification of additional (predicted) genes such as STAT1, IRF9, XAF1, IFI27 and IFITM3 that may also be involved in HCV clearance.
DISCUSSION
This study identified 471 genes that were expressed differentially among anti-HCV antibody-positive individuals that cleared their HCV infection and those that remained chronically infected. This approach was chosen as a means of identifying genes and/or gene pathways that may serve as new gene targets associated with HCV clearance. Ninety-one genes were significantly differentially up-or downregulated by at least twofold, and 15 genes were identified previously by others using in vitro infection models or by studies designed to identify genes associated with positive outcomes following treatment for HCV infections. Seventy-six genes had not been identified previously in the context of HCV clearance and represent novel gene targets potentially associated with HCV clearance or targets that can form the basis for the design of new therapeutic interventions or used to modify existing treatment modalities.
Because flow cytometric analyses designed to define the cell populations present in the buffy coats of the respective infection groups were not carried out at the time RNA was isolated, it is possible that some of the differentially expressed genes identified may have been a result of different cell populations present in the PBMCs of chronically infected individuals (compared with PBMC populations present in individuals who cleared their infections). Previous reports have described increased and decreased numbers of peripheral natural killer and CD8 
Others have identified increased frequencies of CD4
+ and CD8 + regulatory T-cells (Tregs) among individuals chronically infected with HCV compared with uninfected controls (Hartling et al., 2012) , and antibody repertoire differences between chronically infected individuals compared with individuals who cleared their HCV infections have also been reported (Racanelli et al., 2011) . Data from the abovedescribed studies suggested that the cells comprising the PBMC population in HCV chronically infected individuals and individuals who cleared their infections are probably different. However, it is unlikely that all of the 471 differentially expressed genes identified (and the 91 genes differentially expressed by more than twofold) were due strictly to differences between the populations present. More importantly, many of the genes identified as up-or downregulated by more than twofold may not have been associated with cell populations present in different proportions between chronically infected individuals and individuals who cleared their respective infections (e.g. macrophages). Conversely, even if the significantly up-or downregulated genes identified were due entirely to the presence of different cell populations in the PBMC repertoire, this does not take away from the information generated by the analysis described, namely that some genes not previously associated with HCV infections remain potential targets that can be used in the modification of current treatment modalities or in the development of novel treatments.
The genes identified following our analyses were divided into three broad groups: immune function, cancer related and other (e.g. genes associated with cell growth, inflammation, signalling pathways, central nervous system pathways, lipid metabolism, and energy and metabolism pathways). Our comprehensive bioinformatics analyses strongly support a central role for immune response-related genes in HCV clearance.
Of the immune-related genes identified, only genes encoding IFIT2, IFIT3, IRF7, ISG15, MX1, OAS1, OASL, OSM, PLSCR1, TMEM176A, TMEM176B and TRIM22 have been shown previously to play roles in anti-HCV immune responses. In addition, IFIT2, IFIT3, IRF7, ISG15, MX1, OAS1, OASL, OSM and TRIM22 genes were shown to be involved in innate immune responses or to influence HCV antiviral activities.
IFIT2 and IFIT3 have been studied in the context of HCV treatment. Specifically, IFIT1 has been shown to suppress HCV activity in the presence of interferon, and therefore may be beneficial when used in combination with HCV treatment regimens designed to achieve lasting viral suppression (Lalle et al., 2008) . The gene encoding TLR7 (which helps in the regulation of IRF7) is downregulated following HCV infections (by altering TLR7 mRNA stability and function) as an HCV-mediated immune evasion strategy (Chang et al., 2010) . Decreased expression of TLR7 following HCV infections can therefore lead to viral persistence leading to chronic infections (Chang et al., 2010) . HCV also can avoid immune responses by interfering with interferon-stimulating genes (ISGs), for example ISIG15 and OASL, which represent two ISGs that play important roles in mediating innate antiviral responses. Interference with ISG function is likely to result in persistent infections (Jouan et al., 2012) . Finally, interactions between ISG15 and alpha interferon (IFN-a) mediate anti-HCV responses associated with increased expression of the IFN-ainducible genes OAS1 and MX1. Therefore, even though ISG15 does not mediate direct antiviral effects against HCV, Fig. 1 . GeneMANIA analysis of the 91 differentially expressed genes between HCV cleared and persistent infections. Lines represent co-expression, co-localization, physical or predicted interactions between genes as indicated in the legend. Differentially expressed genes identified by this study are represented by grey circles. Genes identified as having potential interactions with the identified genes (based on the GeneMANIA analysis) are represented by white circles.
its role in the modulation of IFN-a genes may mediate antiviral responses (Chua et al., 2009) .
OSM is a cytokine that can play a variety of roles including mediating anti-HCV immune responses in association with IFN-a, suggesting that this cytokine could possibly be used as a new anti-HCV treatment option (Ikeda et al., 2009) . Upregulation of TRIM22 expression has also been described by other microarray analyses in chronically infected HCV patients and shown to possess anti-virus replication activities (Nisole et al., 2005) , including activity against HCV (Folkers et al., 2011) . The PLSCR1 gene has been shown to play a role in protection by interfering with HCV entry into hepatocytes (Gong et al., 2011) ; therefore, interruption of PLSCR1 gene function could inhibit HCV entry into hepatocytes, resulting in diminished viral loads, in addition to its use in the development of novel treatment strategies. TMEM176A and TMEM176B have been shown to be associated with HCV recurrence in a gene expression study of patients with liver transplants (Gehrau et al., 2011) .
Although these genes have been found to possess antiviral activities, the above-mentioned studies were conducted in vitro using various cell-culture approaches or during the course of human studies designed to identify genes associated with anti-HCV drug therapies; therefore, their role during the initial infection process can only be inferred. However, identification of some genes previously associated with HCV clearance served to validate the microarray analysis described in this report that identified additional gene targets. Many previously unidentified genes associated with viral clearance were identified in this study and may also be important in clearing HCV infections. Combining these components into existing therapies may enhance the body's ability to clear HCV infections.
A gene recently associated with HCV clearance is the type III interferon gene, IL28B, which encodes IFN-l3. Most studies have examined the role IL28 in HCV clearance in relation to the efficacy of pegylated IFN-a plus ribavarinbased therapies (Balagopal et al., 2010) . Furthermore, single-nucleotide polymorphisms (SNPs) identified within the IL28 gene in various populations have been shown to affect the effectiveness of pegylated IFN-a plus ribavarin (Shaker & Sadik, 2012; Xie et al., 2012) . It has recently been demonstrated that a SNP (rs12979860) was associated with HCV genotype 1 clearance among vertically infected children and that IFN-l levels in blood and liver were elevated in individuals chronically infected with HCV, resulting in the upregulation of antiviral innate immune responses (by inducing the generation of dendritic cells with the potential of expanding Foxp3 + Tregs) (Dolganiuc et al., 2012) . In addition, IFN-l-mediated control of ISGs (in both humans and chimpanzees) is associated with HCV clearance (Thomas et al., 2012) . The present study identified up-or downregulated genes in individuals who cleared their HCV infections relative to the expression profile observed in chronically infected individuals. IL28 was not among the genes identified; however, all ISGs identified in our study (IFIT2, IRF7, IFIT3, IFI6, IFIT1, IFI35, MX1, ISG15 and OASL; Table 2 ) were significantly downregulated in individuals who had cleared their HCV infections, suggesting that these genes are probably upregulated in chronically infected individuals. As temporal effects relating to IL28 expression in the context of HCV infections have not been established, we cannot rule out the possibility that IL28 levels were upregulated earlier during the infection process or during the earlier stages of chronic infection. It is possible therefore that temporal effects relating to IL28 gene expression in the context of HCV infection may explain why this gene was not identified in our study.
Of the cancer-related genes identified in the present study, only HRK has been studied previously in relation to HCV. HCV can elicit cell death via apoptosis by influencing the activities of different genes responsible for regulating cell death (Walters et al., 2009) , including HRK, and has been linked to cytochrome c release from mitochondria (Walters et al., 2009) .
Two genes, GBP-1 and HDB, did not fit into the three primary categories defined. Itsui et al. (2009) tested the effects of GBP-1 in cell-culture assays and determined that HCV bound GBP-1. Binding of the HCV protein NS5B to GBP-1 resulted in GTPase inhibition (typically mediated by GBP-1), facilitating HCV replication. This may lead to resistance to innate, IFN-mediated antiviral defences and to the clinical persistence of HCV infections (Itsui et al., 2009) . HDC has been studied in the context of treatment but is believed to decrease the oxidative stress that accompanies HCV infections, especially in the liver (Lurie et al., 2002) . HDC binds histamine receptors on phagocytes and subsequently blocks the production of reactive oxygen species produced by monocytes or macrophages (Lurie et al., 2002) . This reduces oxidative damage that optimizes natural killer cell and T-cell function, thereby enhancing immune responses to viral antigens (Lurie et al., 2002) .
As prevalence data were used in this analysis, the time when the respective participants acquired their infections or when the infections were cleared was unknown. However, based on previously published data, participants probably had ample time to clear the virus (Cox et al., 2005; Hofer et al., 2003) . The HCV viral loads were verified at the time of the microarray analysis, which occurred 4-5 years after HCV detection by HCV enzyme immunoassay (EIA). The HCV infection status of all participants was verified, that is, patients defined as infected had positive viral loads and patients identified as having cleared their respective HCV infections had undetectable viral loads. We are currently replicating these studies using an HCVpositive population where HCV RNA status can be verified and the genetic polymorphisms in these candidate genes identified as a means of understanding better the roles of these genes in HCV persistence/clearance.
METHODS
Study population. The study was a nested case-control design. Anti-HCV antibody-positive individuals (n516) were recruited from a longitudinal cohort of an intervention study in their last year of follow-up. Briefly, the intervention study utilized hepatitis B vaccination as a model for a future HIV and HCV vaccine trial that evaluated the efficacy of a hepatitis B self-efficacy behavioural intervention and an accelerated vaccination schedule as methods to increase acceptance/adherence to hepatitis B vaccination among notin-treatment drug users (Hwang et al., 2010) . HIV-and hepatitis B virus-negative participants were enrolled for hepatitis B vaccination and follow-up. All enrolled subjects were tested for anti-HCV antibodies by an EIA at enrolment and at the 6-month visit (for confirmation). If the participant did not have a 6-month sample, the screening sample was tested or a subsequent follow-up visit sample was tested for anti-HCV antibodies. If anti-HCV positive (at least two samples positive at least 6 months apart), the sample was tested for HCV RNA by PCR. For the current study, we recruited eight participants who were anti-HCV antibody positive and HCV RNA positive, and eight individuals who were anti-HCV antibody positive and HCV RNA negative, who were matched by age, sex and race from the larger longitudinal cohort. Informed consent was obtained from each participant and human experimentation guidelines of the USA Department of Health and Human Services and of the University of Texas Health Science Center at Houston Committee for the Protection of Human Subjects were followed in the conduct of this clinical research.
HCV testing. For the previously described longitudinal cohort study (Hwang et al., 2010) , samples were collected in 10 ml tubes, centrifuged within 8 h to separate the serum and immediately stored at 220 uC until tested (mean duration of 1 month). Antibodies to HCV were detected by microparticle EIA (Abbott Laboratories) in serum. Samples positive for anti-HCV antibodies were tested qualitatively for the presence of HCV RNA by PCR (Cobas Amplicor HCV; Roche Diagnostics). Plasma samples from the corresponding participants in this study were analysed for the presence of HCV RNA at the Diagnostic Laboratories of the Memorial Herman Hospital (Houston, TX, USA) using a quantitative PCR test conducted with a lower limit of detection set at ,43 IU ml 21 (Cobas Ampliprep, Cobas TaqMan HCV Real-Time RT-PCR; Roche Diagnostics). All assays were performed according to manufacturers' directions, including running appropriate controls and repeat testing when necessary (Hwang et al., 2010) .
Microarray analysis. Blood was collected in PaxGene (Qiagen) tubes and stored at 280 uC within 8 h of collection, and RNA was extracted using a PAXgene RNA extraction kit (Qiagen) as instructed by the manufacturer,~1 month after collection. Extracted RNA samples were frozen at 220 uC until analysis at the University of Texas Health Science Center at Houston Microarray Core Laboratory using an Illumina Gene Expression chip to identify candidate genes based on RNA expression profiles. The data were analysed using GenomeStudio 1.03 software (Illumina).
Data quality. Raw signals of all built-in controls were checked as quality controls for the performance of the arrays. Sample-independent controls were used to check hybridization and signal generation. Housekeeping genes were used as sample-dependent controls. Data for patient no. 9, an HCV EIA-positive, HCV RNA-negative patient, was excluded due to poor data quality.
Background signals were subtracted and arrays were normalized using quantile normalization (Bolstad et al., 2003) . The reproducibility of biological or technical replicates was checked by comparisons between individual samples. Outliers were removed if necessary, and the remaining samples were grouped and the mean signal intensities between groups used for differential expression analysis.
Statistical analysis. Pre-processing utilized quantile normalization and background subtraction. Differential expression was determined at P,0.05 with multiple testing correction using the BenjaminiHochberg method to control for false discovery rates (Benjamini & Hochberg, 1995) . Clustering and pathway analysis were performed using the Multiple Array Viewer version 4.3.02 (Saeed et al., 2003) and Ingenuity IPA version 8.6.
